Overall survival by blast count in combined groups of MDS with erythroid hyperplasia, AEL, and AML-MRC with erythroid hyperplasia (205 patients total) and of MDS cases without erythroid hyperplasia (179 patients total)
| . | No. of patients in each group . | Median overall survival, mo . | Log-rank test for trend, P . |
|---|---|---|---|
| Combined AEL and MDS/AML-MRC with erythroid hyperplasia cases, stratified by blasts as % of all cells | .71 | ||
| Less than 5 | 30 | 13 | |
| 5-9 | 47 | 8 | |
| 10-14 | 45 | 9 | |
| 15-19 | 42 | 11 | |
| More than 20 | 41 | 10 | |
| Combined AEL and MDS/AML-MRC with erythroid hyperplasia cases, stratified by blasts as a % of nonerythroid cells | .33 | ||
| Less than 10 | 20 | 14 | |
| 10-19 | 20 | 17 | |
| 20-29 | 47 | 6 | |
| More than 30 | 118 | 10 | |
| MDS cases without erythroid hyperplasia, stratified by blasts as % of all cells | < .001 | ||
| Less than 5 | 115 | Not reached | |
| 5-9 | 44 | 16 | |
| 10-19 | 20 | 11 |
| . | No. of patients in each group . | Median overall survival, mo . | Log-rank test for trend, P . |
|---|---|---|---|
| Combined AEL and MDS/AML-MRC with erythroid hyperplasia cases, stratified by blasts as % of all cells | .71 | ||
| Less than 5 | 30 | 13 | |
| 5-9 | 47 | 8 | |
| 10-14 | 45 | 9 | |
| 15-19 | 42 | 11 | |
| More than 20 | 41 | 10 | |
| Combined AEL and MDS/AML-MRC with erythroid hyperplasia cases, stratified by blasts as a % of nonerythroid cells | .33 | ||
| Less than 10 | 20 | 14 | |
| 10-19 | 20 | 17 | |
| 20-29 | 47 | 6 | |
| More than 30 | 118 | 10 | |
| MDS cases without erythroid hyperplasia, stratified by blasts as % of all cells | < .001 | ||
| Less than 5 | 115 | Not reached | |
| 5-9 | 44 | 16 | |
| 10-19 | 20 | 11 |